The Innovation in Psychosis Therapeutics Summit is the premier industry forum dedicated to advancing next-generation approaches for psychosis treatment. As 2025 marks a pivotal year for psychosis drug development—with a surge in clinical advancements and key collaborations gaining momentum—this inaugural event unites the brightest minds in biotech and pharma to overcome critical challenges in drug discovery and development.

Designed specifically for R&D leaders, this summit is uniquely positioned to tackle the biggest hurdles in the field, including translational validity, patient heterogeneity, placebo effect, and trial scalability. By bringing together 60+ key stakeholders from discovery, preclinical, translational, and clinical development, this meeting provides a platform to collaborate, exchange insights, and shape the future of psychosis treatment.

With the growing urgency to address the significant unmet need in psychosis and the limitations of current atypical antipsychotics, the time is now to drive innovation forward. Join the conversation as industry pioneers build on Cobenfy’s breakthrough success and explore cutting-edge strategies to develop more effective, better-tolerated therapeutics across the psychosis spectrum.

Don’t miss this brand-new opportunity to connect with thought leaders, gain critical insights, and be at the forefront of transforming psychosis R&D.

To know more visit: https://ter.li/9yj2vx